Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-559 + metformin
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TAK-559 + metformin is an investigational combination therapy for type 2 diabetes. TAK-559 is a novel small molecule that acts as a dual agonist of human peroxisome proliferator–activated receptor gamma 1 (PPARγ1) and peroxisome proliferator–activated receptor alpha (PPARα), with partial agonist activity at PPARγ1 and slight activity at PPARδ. This mechanism aims to improve insulin sensitivity and lipid metabolism. Metformin, a biguanide, reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity. The combination was studied to evaluate its safety and efficacy in patients with type 2 diabetes who require improved glycemic control[3][6].
- Brand names
- GlucophageGlucophage XR
- Other names
- metformin
02
Targets
ND1 (Mitochondrial electron transport chain complex I)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)PPARD (Peroxisome proliferator–activated receptor delta)
Beyond the preview
Go deeper on TAK-559 + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-559 + metformin.